fatnews.com Fatnews Bitchute Channel Link Home page  >  Article | Previous article | Next article



  • Categories of Articles
  • Summary View
  • Headline View
  • Archive of Quotes
  • Contact Us
  • Symlin (pramlintide) at 360 mcg twice a day caused more weight loss than lower doses

    Posted by .(JavaScript must be enabled to view this email address)
    Thursday, September 11, 2008 2:31 pm Email this article
    When Symlin (pramlintide) was injected twice a day instead of three times per day, 360 mcg caused more weight loss than 240 mcg or 120 mcg according to a new study.

    When given twice a day, injections were given before breakfast and dinner. The lunch dose was skipped.

    "In contrast to three-times-daily dosing regimens, a clear dose-response relationship was evident among twice-daily regimens, whereby 120 [mcg twice a day] was suboptimal and 360 [mcg twice a day] elicited weight loss of a magnitude similar to the three-times-daily regimens," the authors of a new study noted.

    "Thus, at higher doses, twice-daily dosing appears to be a feasible pramlintide regimen for weight loss."

    Comment: In other words, 120 mcg three times per day causes as much weight loss as higher doses, however, if a patient only prefers to give themselves injections twice a day instead of three times per day, then giving 360 mcg twice a day also works. REFERENCE

    Smith S, Aronne L, Burns C, Kesty N, Halseth A, Weyer C. Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care. 2008 Sep, 31(9):1816-23.


    Christian Weyer, MD
    Amylin Pharmaceuticals
    San Diego, California USA
    .(JavaScript must be enabled to view this email address)

    Steve R. Smith, MD
    Pennington Biomedical Research Center
    Louisiana State University
    Baton Rouge, Louisiana USA
    .(JavaScript must be enabled to view this email address)


    Articles on the same subject can be found here:


    Please feel free to share your comments about this article.




    Please enter the word you see in the image below:

    Remember my personal information

    Notify me of follow-up comments?

    © Copyright 2003-2021 - Larry Hobbs - All Rights Reserved.